Of the efficacy outcome studied including MACE, CV death, fatal and non-fatal MI, fatal and non-fatal stroke, HF hospitalization, CV death or HF hospitalization, and all-cause mortality, SGLT2 inhibitors had the greatest impact on reducing hospitalization for HF with an overall 32% reduction compared with placebo, HR 0.68; 95% CI (0.60-0.76) without evidence of heterogeneity between these studies [8]. This evidence concerns the gene SLC5A2 and Stroke.